Skip to content

Syntis is advancing a pipeline of proprietary programs

Program
Discovery
Pre-Clinical
Ind-Enabling
Phase 1
Phase 2
Obesity
SYNT-101
SYNT-113
SYNT-115
SYNT-101
SYNT-101: Polymer Only
SYNT-113
SYNT-113: SYNT + Small Molecule (derisked molecule & target)
SYNT-115
SYNT-115: SYNT + Biologic (derisked target and mechanism)
Rare Diseases
SYNT-212
SYNT-213
SYNT-212
SYNT-212: SYNT + Biologic (established mechanism)
SYNT-213
SYNT-213: SYNT + Biologic (established mechanism)
Other TAs
Oral Bioavailability
Oral Bioavailability
Oral Bioavailability: SYNT + Biologics or Small Molecule Therapeutic
‘Barrier’ Function
Local/Luminal Activity
Systemic Exposure

Obesity

Obesity is a global epidemic, impacting 100 million people in the U.S. and 800 million worldwide—with the latter figure projected to reach 1.5 billion by 2030.

The most effective approaches to weight loss work by controlling the satiety-hormone axis, specifically elevating circulating satiety hormones. This can be reached through bariatric surgery or pharmacologically, such as with GLP-1 therapies. While GLP-1 drugs have achieved unprecedented weight loss for many patients, they rely on sustained circulating drug levels to maintain their effect – which can produce gastrointestinal and other treatment-limiting effects, particularly as doses are escalated.

Our portfolio of obesity therapies may offer an alternative and/or complementary approach intended to provide patients with a more affordable and sustainable path forward.

SYNT-101

Syntis is offering a fundamentally different approach for the treatment of obesity with SYNT-101. This once-daily pill is designed to modulate hormones, but in a different way than GLP-1 or similar drugs. Our therapy is designed to generate a specific multi-hormone signature – one that mimics the metabolic response of bariatric surgery but via a once-daily oral tablet.

SYNT-101 works by acting locally in the gut and forming a transient lining in the duodenum, the upper part of the small intestine, to redirect nutrients to the beyond this region, specifically the distal small intestine. This stimulates a very specific set of satiety and metabolism-regulating hormones, including GLP-1, PYY, and ghrelin, when food is consumed rather than through continuous systemic drug exposure, amplifying the natural response to a meal in the same way bariatric surgery does.

Results from the Company’s Phase 1/1b SYNTIETY-1 (SYNThetic Intestinal ExclusIon Therapy for ObesitY) clinical trial demonstrated that SYNT-101 drove the specific multi-hormone signature observed in bariatric surgery, as well as greater weight loss in SYNT-101 treated participants than those on placebo, which was comparable to weight loss observed with GLP-1 therapies after the same treatment duration. Data also indicated SYNT-101 displayed excellent safety and tolerability across doses, essentially equivalent to placebo, with treatment-related gastrointestinal events being infrequent and transient.
Early, preclinical models have also demonstrated 100% preservation of lean muscle mass with consistent week-to-week weight loss in rodent models.

Obesity Portfolio

Beyond SYNT-101, we are advancing at least two distinct preclinical programs that pair the SYNT platform with proprietary therapeutics built on validated mechanisms of action. Each of our programs is designed with the potential to be used individually or to complement and act synergistically alongside other weight loss therapies, including GLP-1, amylin and more.

Pediatric Rare Disease Portfolio

We are also developing a portfolio of gut-restricted enzyme replacement therapies to address rare metabolic disorders that lack approved treatments.

Our two leading enzyme programs are indicated in orphan pediatric diseases Homocystinuria (SYNT-212) and maple syrup urine disorder (SYNT-213). These enzymes were acquired from Codexis, Inc. in 2024 after eight years of optimization for GI stability. These enzyme therapies have been investigated in multiple pre-clinical studies, including in non-human primates. We are advancing these therapies in combination with SYNT technology to significantly prolong their gut-restricted activity for maximum disease control.

Top